<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01053897</url>
  </required_header>
  <id_info>
    <org_study_id>GBT-09-001</org_study_id>
    <nct_id>NCT01053897</nct_id>
  </id_info>
  <brief_title>Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery</brief_title>
  <official_title>A Phase 2, Multicenter, Double-Blind, Placebo-Controlled Study of GBT009 for Treatment of Incisional Wounds Following Breast Reconstruction Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Garnet BioTherapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Garnet BioTherapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to assess whether intradermal injections of GBT009
      along full thickness incisions following surgery results in an improvement in scar
      appearance.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>January 2010</start_date>
  <completion_date type="Actual">October 2011</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Photography- Independent Scar Assessment Panel</measure>
    <time_frame>0.5, 1, 2, 3, 6, 9 and 12 Months</time_frame>
    <description>An independent panel was planned to review scar photography to determine more preferable outcomes. Panel was not performed.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Scar Preference</measure>
    <time_frame>12 Month (End of Study)</time_frame>
    <description>Overall preference of the healing/appearance of each scar segment as completed by investigator and subject.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient Observer Scar Assessment Scale (POSAS)</measure>
    <time_frame>12 Month (End of Study)</time_frame>
    <description>Rating by subject and investigator (observer) to assess various factors of scar segment appearance/characteristics on a numeric scale (0-10). Individual parameters rated by the subject or observer according to a 0-10 scale where 0 equals no symptoms or difference from normal (better) and 10 equals the worst possible symptoms or difference from normal (worse).
Outcomes measured at 0.5, 1, 2, 3, 6, 9 and 12 Months. Reported Data is end of study (12 months)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Manchester Scar Scale (MSS)</measure>
    <time_frame>12 Month (End of Study)</time_frame>
    <description>Rating by investigator to assess various factors of scar appearance/characteristics on numeric scales.
MSS includes a visual analog scale (10 cm; 0 excellent appearance, 10 poor appearance) and four descriptive characteristics rated 1 to 4 according to the following descriptions.
Color: Perfect (1), Slight mismatch (2), Obvious mismatch (3), Gross mismatch (4).
Contour: Flush with surrounding skin (1), Slightly proud/indented (2), Hypertrophic (3), Keloid (4).
Distortion: None (1), Mild (2), Moderate (3), Severe (4). Texture: Normal (1), Just palpable (2), Firm (3), Hard (4).
Outcomes measured at 0.5, 1, 2, 3, 6, 9 and 12 Months. Reported Data is end of study (12 months)</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Scar Formation</condition>
  <arm_group>
    <arm_group_label>GBT009</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>GBT009</intervention_name>
    <description>Intradermal Injection following surgery</description>
    <arm_group_label>GBT009</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal Injection following surgery</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria: Subjects must meet all of the following criteria to be considered
        eligible to participate in the study:

          -  be a female between 18 and 70 years of age, inclusive

          -  have a body mass index ≤ 32 kg/m2 and a body weight between 50 and 95 kg, inclusive

          -  be scheduled for a mastectomy with breast reconstruction surgery using an abdominal
             flap technique

          -  for women diagnosed with breast cancer, has standard of care treatment for breast
             cancer prior to surgery and will have standard of care treatment for breast cancer
             after surgery

          -  for subjects of childbearing potential, be surgically sterile or using an insertable,
             injectable, transdermal, or combination oral contraceptive approved by the FDA through
             completion of the study and have negative results on a serum pregnancy test done
             before administration of study medication (women who are postmenopausal [no menses for
             at least 2 years] are also eligible to participate)

          -  be able to understand the study procedures, agree to participate in the study program,
             and voluntarily provide written informed consent

        Exclusion Criteria: Subjects who meet any of the following criteria will be excluded from
        participating in the study:

          -  have clinically significant laboratory abnormalities at screening

          -  have, as determined by the investigator or the sponsor's medical monitor, a history or
             clinical manifestations of significant renal, hepatic, cardiovascular, metabolic,
             neurologic, psychiatric, coagulopathic disorder or other condition that would preclude
             participation in the study

          -  have received treatment for a severe, uncontrolled inflammatory disease or allergic
             condition within three months of screening

          -  have a life expectancy ≤ 2 years

          -  have a history of alcoholism or drug addiction or abuse within 5 years

          -  have evidence of a clinically significant abnormality upon evaluation of 12 lead ECG

          -  have evidence of any past or present clinically significant medical condition,
             including skin disease, that would impair wound healing

          -  have a history of keloid scar formation

          -  have existing scarring in the abdominal area of study that would interfere with the
             efficacy assessments

          -  have a history of (within the past 5 years) or an active malignancy, other than breast
             cancer

          -  have a breast cancer that has been staged at Stage IIIB, IIIC or IV

          -  have received a cytotoxic agent or have been treated with radiation within 90 days of
             screening and/or, in the opinion of the investigator, will likely require treatment in
             the 30 day period following the administration of study medication

          -  have received anticoagulation medication within 5 days of dosing with study medication

          -  have participated in any study involving an investigational product within 30 days
             before dosing with study medication

          -  have routinely used tobacco products within 6 months preceding the study period
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Garnet Study Manager</last_name>
    <role>Study Director</role>
    <affiliation>Garnet BioTherapeutics, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Garnet BioTherapeutics Investigational Site</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Garnet BioTherapeutics Investigational Site</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 20, 2010</study_first_submitted>
  <study_first_submitted_qc>January 20, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 22, 2010</study_first_posted>
  <results_first_submitted>March 11, 2013</results_first_submitted>
  <results_first_submitted_qc>August 19, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">October 24, 2013</results_first_posted>
  <last_update_submitted>August 19, 2013</last_update_submitted>
  <last_update_submitted_qc>August 19, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 24, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>GBT009</keyword>
  <keyword>incisional scar</keyword>
  <keyword>breast reconstruction</keyword>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were screened and enrolled at two US centers (surgical practices) beginning in February 2010. The last subject completed participation in October 2011</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>GBT009/Placebo</title>
          <description>All subjects acted as their own control receiving both GBT009 and Placebo</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>GBT009/Placebo</title>
          <description>All subjects acted as their own control receiving both GBT009 and Placebo</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="5"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="48" spread="9.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Photography- Independent Scar Assessment Panel</title>
        <description>An independent panel was planned to review scar photography to determine more preferable outcomes. Panel was not performed.</description>
        <time_frame>0.5, 1, 2, 3, 6, 9 and 12 Months</time_frame>
        <population>All subjects had scar photography completed at study visits. However, due to the early termination of this trial, the independent panel review was not completed.</population>
        <group_list>
          <group group_id="O1">
            <title>GBT009</title>
            <description>All subjects acted as their own control receiving both GBT009 and Placebo</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>All subjects acted as their own control receiving both GBT009 and Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Photography- Independent Scar Assessment Panel</title>
          <description>An independent panel was planned to review scar photography to determine more preferable outcomes. Panel was not performed.</description>
          <population>All subjects had scar photography completed at study visits. However, due to the early termination of this trial, the independent panel review was not completed.</population>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="0"/>
                <count group_id="O2" value="0"/>
              </count_list>
            </analyzed>
          </analyzed_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Scar Preference</title>
        <description>Overall preference of the healing/appearance of each scar segment as completed by investigator and subject.</description>
        <time_frame>12 Month (End of Study)</time_frame>
        <population>All Subjects included.</population>
        <group_list>
          <group group_id="O1">
            <title>GBT009</title>
            <description>GBT009 treated scar segment preferred</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treated scar segment preferred</description>
          </group>
          <group group_id="O3">
            <title>No Difference</title>
            <description>No scar segment was preferred to the other</description>
          </group>
        </group_list>
        <measure>
          <title>Overall Scar Preference</title>
          <description>Overall preference of the healing/appearance of each scar segment as completed by investigator and subject.</description>
          <population>All Subjects included.</population>
          <units>participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
                <count group_id="O3" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Investigator Evaluation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject Evaluation</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="2"/>
                    <measurement group_id="O3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Patient Observer Scar Assessment Scale (POSAS)</title>
        <description>Rating by subject and investigator (observer) to assess various factors of scar segment appearance/characteristics on a numeric scale (0-10). Individual parameters rated by the subject or observer according to a 0-10 scale where 0 equals no symptoms or difference from normal (better) and 10 equals the worst possible symptoms or difference from normal (worse).
Outcomes measured at 0.5, 1, 2, 3, 6, 9 and 12 Months. Reported Data is end of study (12 months)</description>
        <time_frame>12 Month (End of Study)</time_frame>
        <population>All subjects were included</population>
        <group_list>
          <group group_id="O1">
            <title>GBT009</title>
            <description>Therapy treated scar segment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treated scar segment</description>
          </group>
        </group_list>
        <measure>
          <title>Patient Observer Scar Assessment Scale (POSAS)</title>
          <description>Rating by subject and investigator (observer) to assess various factors of scar segment appearance/characteristics on a numeric scale (0-10). Individual parameters rated by the subject or observer according to a 0-10 scale where 0 equals no symptoms or difference from normal (better) and 10 equals the worst possible symptoms or difference from normal (worse).
Outcomes measured at 0.5, 1, 2, 3, 6, 9 and 12 Months. Reported Data is end of study (12 months)</description>
          <population>All subjects were included</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Vascularization (Observer)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.79"/>
                    <measurement group_id="O2" value="4.6" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pigmentation (Observer)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.4" spread="1.14"/>
                    <measurement group_id="O2" value="4.4" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thickness (Observer)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="2.07"/>
                    <measurement group_id="O2" value="2.6" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Relief (Observer)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="1.82"/>
                    <measurement group_id="O2" value="3.4" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pliability (Observer)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="1.41"/>
                    <measurement group_id="O2" value="2.4" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Pain (Subject)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Itching (Subject)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" spread="0"/>
                    <measurement group_id="O2" value="1" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Color (Subject)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.4" spread="2.88"/>
                    <measurement group_id="O2" value="4.6" spread="3.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Stiffness (Subject)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.4" spread="3.78"/>
                    <measurement group_id="O2" value="3" spread="3.94"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thickness (Subject)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.8" spread="3.56"/>
                    <measurement group_id="O2" value="3.8" spread="3.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Irregularity (Subject)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4" spread="2.74"/>
                    <measurement group_id="O2" value="4" spread="2.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Manchester Scar Scale (MSS)</title>
        <description>Rating by investigator to assess various factors of scar appearance/characteristics on numeric scales.
MSS includes a visual analog scale (10 cm; 0 excellent appearance, 10 poor appearance) and four descriptive characteristics rated 1 to 4 according to the following descriptions.
Color: Perfect (1), Slight mismatch (2), Obvious mismatch (3), Gross mismatch (4).
Contour: Flush with surrounding skin (1), Slightly proud/indented (2), Hypertrophic (3), Keloid (4).
Distortion: None (1), Mild (2), Moderate (3), Severe (4). Texture: Normal (1), Just palpable (2), Firm (3), Hard (4).
Outcomes measured at 0.5, 1, 2, 3, 6, 9 and 12 Months. Reported Data is end of study (12 months)</description>
        <time_frame>12 Month (End of Study)</time_frame>
        <group_list>
          <group group_id="O1">
            <title>GBT009</title>
            <description>Therapy treated scar segment</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo treated scar segment</description>
          </group>
        </group_list>
        <measure>
          <title>Manchester Scar Scale (MSS)</title>
          <description>Rating by investigator to assess various factors of scar appearance/characteristics on numeric scales.
MSS includes a visual analog scale (10 cm; 0 excellent appearance, 10 poor appearance) and four descriptive characteristics rated 1 to 4 according to the following descriptions.
Color: Perfect (1), Slight mismatch (2), Obvious mismatch (3), Gross mismatch (4).
Contour: Flush with surrounding skin (1), Slightly proud/indented (2), Hypertrophic (3), Keloid (4).
Distortion: None (1), Mild (2), Moderate (3), Severe (4). Texture: Normal (1), Just palpable (2), Firm (3), Hard (4).
Outcomes measured at 0.5, 1, 2, 3, 6, 9 and 12 Months. Reported Data is end of study (12 months)</description>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Visual Analog Scale (0-10)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.26" spread="2.62"/>
                    <measurement group_id="O2" value="4.26" spread="2.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Color (1-4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.6" spread="0.55"/>
                    <measurement group_id="O2" value="2.4" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Contour (1-4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="0.55"/>
                    <measurement group_id="O2" value="1.4" spread="0.55"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distortion (1-4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.8" spread="0.45"/>
                    <measurement group_id="O2" value="1.8" spread="0.45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Texture (1-4)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.8" spread="1.79"/>
                    <measurement group_id="O2" value="4.6" spread="1.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year</time_frame>
      <group_list>
        <group group_id="E1">
          <title>GBT009/Placebo</title>
          <description>All subjects acted as their own control receiving both GBT009 and Placebo</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac failure congestive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Toxic shock syndrome streptococcal</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Streptococcal infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Breast cancer metastatic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Dyspnoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Implantable defibrillator insertion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>MedDRA (12.0)</default_vocab>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="5" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Ecchymosis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Oropharyngeal pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Flank pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Subcutaneous abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Upper respiratory tract infection</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Urinary Tract Infection</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Seroma</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Back Pain</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="5"/>
              </event>
              <event>
                <sub_title>Arthralgia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Vaginitis bacterial</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Incisional drainage</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="5"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Study was discontinued early due to difficulty in identifying and enrolling eligible subjects.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Gerri Henwood, CEO</name_or_title>
      <organization>Garnet BioTherapeutics, Inc.</organization>
      <phone>484-395-2440</phone>
      <email>ghenwood@garnetbio.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

